Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03654144

Enrollment

100

Registered

2018-08-31

Start date

2018-11-30

Completion date

2020-03-31

Last updated

2018-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenomyosis

Brief summary

Adenomyosis was first described as endometrial glands in the myometrium of the uterus. The current definition of adenomyosis is provided in 1972 'the benign invasion of endometrium into the myometrium, producing a diffusely enlarged uterus which microscopically exhibits ectopic non-neoplastic, endometrial glands and stroma surrounded by the hypertrophic and hyperplastic myometrium

Interventions

DRUGDienogest

oral tablets

DRUGCombined Oral Contraceptive

oral tablets

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

40 Years to No maximum

Healthy volunteers

Inclusion criteria

* symptomatic adenomyosis * irregular menstrual bleeding and dysmenorrhea .

Exclusion criteria

* asymptomatic patients - * non-lactating patient * not desire for pregnancy * no hormonal treatment more than 6 month even contraception e.g IUD * no focal lesion of uterus (malignancy ,fibroid or adenxal mass )

Design outcomes

Primary

Measure	Time frame	Description
The mean pain score after receiving treatment	6 months	assessment by visual analog scale

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026